As of November 10, 2026, 8 holders' latest Schedule 13D or 13G filings report owning 5% or more of Arrivent Biopharma Inc. The largest reported stake is Suvretta Capital Management, LLC's, at 9.9%. 19 filings are on record since August 13, 2025 (Schedule 13G/A, August 13, 2025).
Sell to companies like Arrivent Biopharma Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Fmr LLC · Sole voting: 2,862,873 · Shared voting: 0 · Sole dispositive: 2,863,340 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-11-05
- · Reporting person: Vivo Opportunity Fund Holdings, L.P. · Sole voting: 1,514,446 · Shared voting: 0 · Sole dispositive: 1,514,446 · Shared dispositive: 0 · SCHEDULE 13G, 2026-10-13
- · Reporting person: Orbimed Advisors LLC · Sole voting: 0 · Shared voting: 2,875,962 · Sole dispositive: 0 · Shared dispositive: 2,875,962 · SCHEDULE 13D/A, 2026-10-08
- · Reporting person: BlackRock, Inc. · Sole voting: 3,130,621 · Shared voting: 0 · Sole dispositive: 3,182,080 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-27
- · Holder: Fmr LLC · Percent: 6.8% · SCHEDULE 13G/A
Arrivent Biopharma Inc has 19 Schedule 13D or 13G filings on record since 2025-08-13. 8 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 9.9% | 3,412,788 | SCHEDULE 13G/A, 2025-08-13 | 2025-06-30 |
| Infinitum Asset Management, LLC | 9.9% | 4,123,923 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| Hillhouse Investment Management, Ltd. | 9.5% | 3,929,117 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| BlackRock, Inc. | 6.8% | 3,182,080 | SCHEDULE 13G/A, 2026-07-27 | 2026-06-30 |
| Orbimed Advisors LLC | 5.8% | 2,875,962 | SCHEDULE 13D/A, 2026-10-08 | 2026-10-06 |
| Fmr LLC | 5.8% | 2,863,340 | SCHEDULE 13G/A, 2026-11-05 | 2026-09-30 |
| HBM Healthcare Investments (Cayman) Ltd. | 5.4% | 2,195,014 | SCHEDULE 13G, 2025-10-15 | 2025-10-08 |
| Vivo Opportunity, LLC | 5% | 2,472,701 | SCHEDULE 13G, 2026-10-13 | 2026-10-06 |
| Novo Holdings A/S | 4.9% | 1,872,142 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Octagon Capital Advisors LP | 4.9% | 1,971,054 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| The Vanguard Group | 4.52% | 1,869,266 | SCHEDULE 13G/A, 2026-01-30 | 2025-12-31 |
| Sofinnova Venture Partners XI, L.P. ("SVP XI") | 4.1% | 1,696,752 | SCHEDULE 13G/A, 2026-03-05 | 2025-12-31 |
Holding shares or following this stake? See who's behind Arrivent Biopharma Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Arrivent Biopharma Inc and the records around it.
Arrivent Biopharma Inc elsewhere on the record
Companies that share a holder
- Sofinnova Venture Partners XI, L.P. ("SVP XI") also filed stake reports on 1 other company: NextCure, Inc. (Mar 2026)
- Hillhouse Investment Management, Ltd. also filed stake reports on 2 other companies: Smart Share Global Limited (May 2026), Webull Corp (Feb 2026)
- HBM Healthcare Investments (Cayman) Ltd. also filed stake reports on 7 other companies: Chemomab Therapeutics Ltd. (Sep 2026), ALX ONCOLOGY HOLDINGS INC (May 2026), IO Biotech, Inc. (Apr 2026)
Watch Arrivent Biopharma Inc
Get an email when Arrivent Biopharma Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Arrivent Biopharma Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Arrivent Biopharma Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Arrivent Biopharma Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
20 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 3,130,621 | 0 | 3,182,080 | 0 | SCHEDULE 13G/A, 2026-07-27 |
| Orbimed Advisors LLC | 0 | 2,875,962 | 0 | 2,875,962 | SCHEDULE 13D/A, 2026-10-08 |
| OrbiMed Capital GP VIII LLC | 0 | 1,437,981 | 0 | 1,437,981 | SCHEDULE 13D/A, 2026-10-08 |
| OrbiMed Asia GP IV, L.P. | 0 | 1,437,981 | 0 | 1,437,981 | SCHEDULE 13D/A, 2026-10-08 |
| OrbiMed Advisors IV Limited | 1,437,981 | 0 | 1,437,981 | 0 | SCHEDULE 13D/A, 2026-10-08 |
| Fmr LLC | 2,862,873 | 0 | 2,863,340 | 0 | SCHEDULE 13G/A, 2026-11-05 |
| Abigail P. Johnson | 0 | 0 | 2,863,340 | 0 | SCHEDULE 13G/A, 2026-11-05 |
| Vivo Opportunity Fund Holdings, L.P. | 1,514,446 | 0 | 1,514,446 | 0 | SCHEDULE 13G, 2026-10-13 |
| Vivo Opportunity Co-Invest, L.P. | 176,752 | 0 | 176,752 | 0 | SCHEDULE 13G, 2026-10-13 |
| Vivo Opportunity Co-Invest (Cycle 3), L.P. | 781,503 | 0 | 781,503 | 0 | SCHEDULE 13G, 2026-10-13 |
| Vivo Opportunity, LLC | 2,472,701 | 0 | 2,472,701 | 0 | SCHEDULE 13G, 2026-10-13 |
| Vivo Opportunity Cayman Fund, L.P. | 152,971 | 0 | 152,971 | 0 | SCHEDULE 13G, 2026-10-13 |
| Vivo Opportunity Cayman, LLC | 152,971 | 0 | 152,971 | 0 | SCHEDULE 13G, 2026-10-13 |
The latest filing identifies Arrivent Biopharma Inc by CUSIP 04272N102 and gives its principal executive office as 18 CAMPUS BLVD, SUITE 100, NEWTOWN SQUARE, PA 19073-3269 (SCHEDULE 13G/A, 2026-11-05).
Source of funds (Item 3)
Not applicable.Orbimed Advisors LLC, SCHEDULE 13D/A, 2026-10-08
Purpose of Transaction (Item 4)
Orbimed Advisors LLC
The Shares acquired by the Reporting Persons were acquired for the purpose of making an investment in the Issuer and not with the intention of acquiring control of the Issuer's business on behalf of the Reporting Persons' respective advisory clients. The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. Except as set forth in this Schedule 13D, the Reporting Persons have not formulated any plans or …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-10-08; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-13 | Suvretta Capital Management, LLC | 9.9% | SCHEDULE 13G/A |
| 2025-08-13 | Orbimed Advisors LLC | 7.5% | SCHEDULE 13D/A |
| 2025-08-13 | Infinitum Asset Management, LLC | 9.9% | SCHEDULE 13G |
| 2025-08-14 | Novo Holdings A/S | 4.9% | SCHEDULE 13G/A |
| 2025-10-15 | HBM Healthcare Investments (Cayman) Ltd. | 5.4% | SCHEDULE 13G |
| 2025-10-17 | BlackRock, Inc. | 4.9% | SCHEDULE 13G/A |
| 2025-10-30 | The Vanguard Group | 5% | SCHEDULE 13G |
| 2025-11-05 | Fmr LLC | 8.4% | SCHEDULE 13G/A |
| 2025-11-14 | Octagon Capital Advisors LP | 4.9% | SCHEDULE 13G/A |
| 2026-01-21 | BlackRock, Inc. | 5.6% | SCHEDULE 13G |
| 2026-01-30 | The Vanguard Group | 4.52% | SCHEDULE 13G/A |
| 2026-02-17 | Hillhouse Investment Management, Ltd. | 9.5% | SCHEDULE 13G/A |
| 2026-02-17 | Infinitum Asset Management, LLC | 9.9% | SCHEDULE 13G/A |
| 2026-03-05 | Sofinnova Venture Partners XI, L.P. ("SVP XI") | 4.1% | SCHEDULE 13G/A |
| 2026-05-06 | Fmr LLC | 6.8% | SCHEDULE 13G/A |
| 2026-07-27 | BlackRock, Inc. | 6.8% | SCHEDULE 13G/A |
| 2026-10-08 | Orbimed Advisors LLC | 5.8% | SCHEDULE 13D/A |
| 2026-10-13 | Vivo Opportunity, LLC | 5% | SCHEDULE 13G |
| 2026-11-05 | Fmr LLC | 5.8% | SCHEDULE 13G/A |
Questions about who owns Arrivent Biopharma Inc
Who owns Arrivent Biopharma Inc?
On this page, 8 holders' latest ownership filings report 5% or more of Arrivent Biopharma Inc: Suvretta Capital Management, LLC (9.9%, Schedule 13G/A, filed 2025-08-13), Infinitum Asset Management, LLC (9.9%, Schedule 13G/A, filed 2026-02-17), Hillhouse Investment Management, Ltd. (9.5%, Schedule 13G/A, filed 2026-02-17), BlackRock, Inc. (6.8%, Schedule 13G/A, filed 2026-07-27) and Orbimed Advisors LLC (5.8%, Schedule 13D/A, filed 2026-10-08); 3 more are listed above.
Who are the largest shareholders of Arrivent Biopharma Inc?
By the share each holder's latest filing reports, the largest holders of Arrivent Biopharma Inc on this page are Suvretta Capital Management, LLC (9.9%), Infinitum Asset Management, LLC (9.9%) and Hillhouse Investment Management, Ltd. (9.5%).
When did Suvretta Capital Management, LLC buy into Arrivent Biopharma Inc?
The filings give report dates, not purchase dates. The earliest filing from Suvretta Capital Management, LLC on this page is the Schedule 13G/A, filed 2025-08-13, reporting 9.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 19 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Arrivent Biopharma Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 9, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Arrivent Biopharma Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.